DEA opens Form 225 registration choices for medical cannabis firms
The live application separates medical marijuana manufacturers, distributors and labs; state licences remain a condition of registration.
Theo Marchetti
The U.S. Drug Enforcement Administration opened separate Form 225 application choices for medical marijuana manufacturers, distributors and analytical laboratories on Oct. 5, Cannabis Business Times reported; the live federal form lists all three. For Curaleaf Holdings, Inc. TSECURA OTCMKTSCURLF and Trulieve Cannabis Corp. NYSETRLV, Form 225's three specialized categories show a possible filing route for qualifying medical businesses, with no company registration shown on that public form.
The Justice Department's April 23 announcement said its order placed FDA-approved products containing marijuana and products regulated under qualifying state medical licences in Schedule III. The department began a separate administrative process to consider broader rescheduling. Its April announcement set June 29 for a hearing on that wider question, distinct from the registration route for the already covered medical products. The new Form 225 choices concern registration within that limited medical framework; they do not themselves extend the April order to adult-use products.
Curaleaf shares TSECURA closed at C$14.22 on the Toronto Stock Exchange at 4 p.m. EDT on Oct. 6, up 2.01 per cent from the previous close, according to Google Finance. The quoted close is a market snapshot, while the DEA application page does not disclose whether Curaleaf or Trulieve has received a registration under the new categories.
The Form Separates Medical Activities
The DEA application offers medical marijuana manufacturer, distributor and analytical lab selections alongside the agency's existing general entries for those activities. A separate dispensary selection appears under the retail category. The registration guide identifies Form 224M for medical marijuana dispensaries and Form 225 for manufacturers, distributors and laboratories.
Applicants must supply business and contact details, the activity and drug schedule, state licences, background information and payment before confirming the submission. The online application breaks those requirements into six sections, with email validation between the business details and the activity selection. DEA warns that choosing the wrong business category can delay an application or cause its withdrawal.
"It is mandatory to provide State medical and/or controlled substance licenses/registrations," the DEA says on its application page.
The agency says state licences must be valid and active; invalid credentials make an application defective and trigger withdrawal without a refund. Application fees are nonrefundable, and no registration is issued until the completed form has been received under 21 CFR 1301.13.
The state-licence field is the threshold for any medical operator seeking this federal registration route. For Curaleaf and Trulieve shareholders, the next issuer-specific evidence would be a company filing identifying an eligible applicant or a DEA registration decision; the agency's public menu supplies neither. The form also gives no basis to assign a Section 280E tax effect to either stock.
Read more: Treasury and IRS prioritize Section 280E guidance for cannabis tax
The DEA's three specialized choices were visible on Oct. 7. A dated company disclosure or agency registration decision would establish whether either issuer has moved through one of them.
